April 23, 2019
A blank slate impedes the sector; otherwise we are relegated to the outcomes of traders, pools and algorithms
What goes down always comes back, it just timing – plant your fingers near a BUY button and risk a move
News: Athersys (ATHX) partner, HEALIOS K.K. has enrolled the first patient in its ONE-BRIDGE study in Japan, evaluating MultiStem® cell therapy treatment of patients who suffer from acute respiratory distress syndrome (ARDS)
Pre-open indications: 4 BUYs, 1 SELL and 3 TRADEs
If you think you understand perception, review your “positions” and think again then again. There is a “heck” of a lot of negative sentiment; liquidity remains a cause for concern!
April 11, 2019
Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes?
Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019?
Why spend time finding sector news and analytics … it’s all right here!
April 23, 2019
As I stated this a.m., “What goes down always comes back, it just timing – plant your fingers near a BUY button and risk a move”
Pre-open indications: 7 HITs and 1 MISS
Insight is about understanding sentiment … while many talk about perception, I monitor the pulse and focus of daily outcomes!
Be a subscriber and miss the pricing oppurtunity or a downturn breakdown!
April 11, 2019
Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes? Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here!
March 31, 2019
A scorecard of (AKA) earnings of 45 covered companies 44 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - it's a reflection of this universe's investing "status"
March 19, 2019
SAGE closed down -$0.78 to $156.10 and is UP +$7.91 or 5.07% to $164.01 in the aftermarket Zulresso is designed to reduce depression symptoms by targeting receptors of the neurotransmitter known as GABA, helping restore the normal balance in the brain that is disrupted around the time of childbirth.
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
